Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
about
VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuseAge-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington diseaseCorticostriatal Dysfunction in Huntington's Disease: The BasicsModulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseasesStriatal cholinergic interneuron regulation and circuit effectsMolecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neuronsCholinergic neuronal defect without cell loss in Huntington's disease.Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's DiseaseTetrabenazine is neuroprotective in Huntington's disease mice.Abnormal motor cortex excitability in preclinical and very early Huntington's disease.Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease.Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Molecular mechanisms and potential therapeutical targets in Huntington's disease.The cholinergic system and neostriatal memory functions.Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.The role of dopamine in Huntington's disease.Dopamine and Huntington's disease.Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease.Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's DiseaseDysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationCholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input.Centrality of striatal cholinergic transmission in Basal Ganglia function.Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias.Disrupted striatal neuron inputs and outputs in Huntington's disease.The VAChTY49N mutation provides insecticide-resistance but perturbs evoked cholinergic neurotransmission in Drosophila
P2860
Q22242306-E0E07E05-6237-481E-B5E5-A60125CCBEF0Q24657764-6CF8D40C-F9C5-4570-8D44-B08309BDF68EQ26738379-0894410A-5629-4CA1-AF87-6AC92C66B369Q26830654-B192CFCF-0E95-41F9-9E7A-B4579BA2B8FAQ26863113-E39306CE-2C06-4EF2-B49D-739D43631A9AQ28207970-FD6BA4AD-D52D-4424-91F0-92EB0A81356AQ33258207-2A9650B5-5ABE-422C-8505-C2F90BA43017Q33813021-6ED930B8-D344-446F-95B9-6A3893C561D6Q33863426-97277F4A-D2C6-46BB-BF2B-2EAFCD75DD8FQ34386162-0313D1AC-5ED0-4B04-98EB-858CE40FC062Q34673305-D66AA2D3-6E84-4000-BF37-D398FF7EEEADQ35049600-7662E54D-D56B-4EA9-A75A-FCAC0028092EQ35116551-E8A04065-6B55-4B33-AFA8-191A89BF0616Q35839434-48B60C02-D164-4A50-A1D0-CB9DFE1241FEQ36079830-190ADE2C-689A-4292-AEDA-25A3F1138432Q37591449-E277A60A-1848-4E1C-A9D1-E95731928D44Q37776087-C1DF88D4-FD83-4008-9681-B50090C1C14EQ37815578-8F1418AB-16BE-4E24-8A17-18D63A4873B4Q38121068-1B833B5D-2286-4D0F-B7EC-36D2029F1C2FQ38223504-63C85D8B-6E69-43F7-89F3-C5326F7EFC1CQ38379277-7343BA94-C7D0-4CB6-84F5-D28CCE1E1FAAQ38533480-E6315882-981F-4EE8-AE7F-14191A6C74A1Q39041214-BC820E72-C2D6-4058-B114-56A1CD09C2DAQ39041217-01A8065C-955E-4437-8D5F-5B6CCDBBC54FQ39740166-4C7178D6-13D3-44A4-99E9-29E47544CCD7Q41915908-757B4F56-AFDF-4FA0-94D7-63316A2E128EQ44060087-B6051C6D-447D-4FBB-9B7F-C75CCB5F4A8BQ52690256-7049C38C-675E-4A13-B790-C900C717F7EDQ58752181-09B1F736-BA17-4A83-B554-D5D717C1DE21
P2860
Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@en
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@nl
type
label
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@en
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@nl
prefLabel
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@en
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@nl
P2093
P2860
P356
P1433
P1476
Vesicular neurotransmitter tra ...... traditional synaptic markers.
@en
P2093
P2860
P304
P356
10.1002/SYN.1089
P577
2001-09-01T00:00:00Z